Dianthus Therapeutics is on a mission to reduce the number of injections autoimmune disease patients have to receive, using $100 million in series A financing to send its antibody candidate into the ...

Dianthus Therapeutics (NASDAQ:DNTH) announced a licensing deal worth up to $1B with Nanjing Leads Biolabs on Thursday to obtain exclusive rights to an autoimmune disease therapy developed by the ...

A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

An update from Nanjing Leads Biolabs Co., Ltd. Class H ( ($HK:9887) ) is now available. Nanjing Leads Biolabs Co., Ltd. announced that its drug ...

Dianthus Therapeutics (DNTH) revealed a new licensing agreement with Nanjing Leads Biolabs for the global rights to DNTH212, a promising autoimmune disease treatment, outside Greater China. The FDA ...

Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase ...

Dianthus Therapeutics (NASDAQ:DNTH) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of ...

Across the recent three months, 5 analysts have shared their insights on Dianthus Therapeutics DNTH, expressing a variety of opinions spanning from bullish to bearish. The table below provides a ...

CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) and Dianthus Therapeutics, Inc. (“Dianthus”), a ...

Something special is growing in my garden, an unexpected treasure. I love seed packets for their retro beauty, so I'm often extracting the seeds (without damaging the package) and planting them in my ...